Advanced, higher priced biologics push the US OrthoBio Market higher

Based on Q418/FY18  SmartTRAK Financial Dashboard reporting:

• US Bone Replacement grew +2.3% YoY, with FY18 revenues up +2.7%.
• US Cartilage Replacement increased 55.7% YoY, with FY18 revenues up 34.7%.
• US Soft Tissue Augmentation grew 2.3%, with FY18 revenues growing 9.2%.
• US Tendon Allografts posted an 8.4% YoY increase, with FY18 revenues up +3.9% YoY
• US Meniscal Implant market, with robust growth, was up 15.6% YoY for Q418 with FY18 revenues increasing by 3.0%.

Among the many topics covered in the Q418/FY18 OrthoBio Market Recap are:

SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc."

The US Surgical Matrices Market continued to advance in Q418, driven by a resurgence of Becton Dickinson in hernia matrices and continued growth of breast matrices.  The US market grew +9.7% in FY18.

SmartTRAK reports that the US Surgical Matrices market grew in both the Breast and Hernia Repair segments. SmartTRAK estimates the Breast segment grew again at +21.8% YoY growth to 35.2% share of the entire Surgical Matrices market. The Hernia Repair market continued its recovery up +4.8% YoY and 64.8% share of the US Surgical Matrices Market in Q418.  

Among the many topics covered in the Q418/FY18 Surgical Matrices Market Recap are:

FY18 showed solid gains in all segments, up +5.7% YoY, as antimicrobial devices take the lead.

Q418 US Spine market remains fairly flat, rounding out a stable but unremarkable FY18.

SmartTRAK’s Financial Dashboard indicates a fairly flat Q418 US Spine market, with a decline of -0.4%. Similarly, for the full year, the US Spine Market was stable, with +0.9% growth. WW revenues increased modestly with a +1% uptick for FY2018. Spine market growth as a whole slowed sequentially to +1% in Q418 from +2% in Q3 according to estimates. Growth continues to be restricted in the US Spine market by a few key factors. Payer pushback is the norm, and while most surgical practices have learned to deal with it, the environment is ever-changing with new obstacles and hurdles.

Among the many topics covered in SmartTRAK's Q418/FY18 Spine Market Recap are:

SmartTRAK Subscribers: See only news for the Markets, Modules and Segments and TYPES of content that you care about!

Have you ever wished that you could customize your SmartTRAK Daily Updates Email so that you can see ONLY news about the SmartTRAK Markets, Modules & Segments as well as Type of content that you care about (like skipping all the Patent updates)?

And that you could save yourself time from scrolling through all the Markets, Modules and Segments that your company subscribes to? 

Pricing pressure and tough comps slow year end growth

SmartTRAK reports that pricing pressure and a slow down in elective procedures impacted the Extremities market overall, with US Market growth down sequentially from +4.7% seen in Q318 to +3.5% in Q418. The Extremities market no longer seems to be able to fly under the radar and, as healthcare facilities look to maximize reimbursement in all areas, pricing for legacy products are facing discounting. In addition to pricing pressure, economic uncertainty in the US during Q4 led to some healthcare consumers choosing to put off elective procedures...

Among the many topics covered in the Q418/FY18 Extremities Market Recap:

Following the last fall's Advanced Wound Care meeting, SmartTRAK's Susan Paquette, VP Wound, reported on advances in negative pressure wound therapy (NPWT), fiber dressings and human dermal tissue and the latest research and company news, identifying what’s new and what’s next in the market for advanced wound care.

Revenues down again, owing to intense competitive pricing pressures

Pricing pressure continued to negatively impact the US Joint Fluid market, which experienced a decline of -7.9% based on Q418 revenues according to SmartTRAK Financial Dashboard. While this market continued to see unit volume increases, ASPs experienced notable declines over the past four quarters as a result of several companies not listing ASPs to CMS, which fueled competitive pricing. Additionally, revenues were impacted by the Anthem non-coverage decision that took effect in Q118 and kept impacting suppliers over the course of the year...

Among the many topics covered in the Q418/FY18 Joint Fluid Market Recap:

Typically, Q4 is a rebound quarter for Total Joints, but SmartTRAK reports that the Q418 US market experienced a sequential decline in growth from Q318’s unseasonably strong growth, due in part to easier YoY comps. In addition, Q4 growth was also slower than the same period last year. FY18 results for the US TJR market confirms a slowing in revenue growth compared to FY17. SmartTRAK believes that increased pricing pressure and a deceleration in procedure volumes during Q4 contributed to the lower growth...